Key highlights
- Achieved 100% confirmed overall response rate in PD-L1 positive first-line ESCC patients
- Reported 89% confirmed overall response rate in evaluable first-line patients irrespective of PD-L1 status
- Demonstrated clinical proof-of-concept for tagmokitug as a first-in-class cytolytic CCR8 antibody
- Observed durable disease stabilization in immunotherapy-resistant and pretreated solid tumor patients
- Supported expansion of enrollment in both first-line and second-line ESCC cohorts
Clinical Data Breakdown
The clinical results focus on tagmokitug, a CCR8-targeted regulatory T-cell depleter, evaluated in the TREGCHECK 102 study alongside toripalimab and chemotherapy. In the first-line setting, 10 patients were safety evaluable and 9 were efficacy evaluable following the October 14, 2026, data cutoff. The 100% response rate observed in PD-L1 positive patients significantly exceeds the historical US standard-of-care benchmarks, which typically range between 44% and 59% for PD-1 and chemotherapy combinations. Furthermore, the combination showed activity in PD-L1 negative patients, a group for which no PD-1 inhibitors are currently approved in the US.
Strategic Development Path
- Expansion of first-line and second-line ESCC cohorts to further validate efficacy and safety
- Targeting CCR8-positive regulatory T cells to overcome immune resistance in difficult-to-treat cancers
- Leveraging toripalimab's established presence in ex-US markets like Europe and China
- Development focused on the high-burden esophageal cancer demographic, particularly in Asia
- Advancement of the cytolytic CCR8 antibody as a cornerstone of the company's IO pipeline
Executive Perspective on Proof-of-Concept
“The totality of these interim data provides clinical proof of concept for tagmokitug, strengthens our confidence in the selected go-forward dose, and integrated development strategy.”
Financial and Operational Context
Coherus Oncology is transitioning toward a pure-play innovative oncology firm, having recently engaged Oppenheimer & Co. to sell its legacy biosimilar assets. The company reaffirmed its full-year 2026 revenue guidance for LOQTORZI between $57 million and $62 million, with operating expenses projected at $170 million to $175 million. To bolster its balance sheet, Coherus entered a $50 million at-the-market equity sales agreement in August 2026. These clinical results arrive as the company prepares to report its third-quarter 2026 financial results on November 9, 2026.
Down 56.4% since our story on 29 Oct: $1.16 when we broke it → $0.51 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $0.96 |
|---|---|
| 20 Oct | $1.00 |
| 21 Oct | $1.02 |
| 22 Oct | $1.05 |
| 23 Oct | $1.01 |
| 26 Oct | $1.01 |
| 27 Oct | $1.07 |
| 28 Oct | $1.16 |
| 29 Oct | $0.90 |
| 30 Oct | $0.83 |
| 2 Nov | $0.75 |
| 3 Nov | $0.81 |
| 4 Nov | $0.85 |
| 5 Nov | $0.75 |
| 6 Nov | $0.77 |
| 9 Nov | $0.82 |
| 10 Nov | $0.64 |
| 11 Nov | $0.58 |
| 12 Nov | $0.54 |
| 13 Nov | $0.53 |
| 16 Nov | $0.51 |
| Date | Announcement | Amount |
|---|---|---|
| 28 Oct 2026 | Interim clinical data for tagmokitug in esophageal cancer and path to advance developmentSource: investors.coherus.com | – |
| 23 Sep 2026 | Retained Oppenheimer & Co. to market and sell legacy biosimilar assetsSource: investors.coherus.com | – |
| 28 Aug 2026 | At-the-market equity sales agreement with Leerink Partners LLCSource: SEC filing | $50.0 Million |
| 17 Aug 2026 | Declared special dividend of legacy biosimilar contingent value rights (CVRs)Source: SEC filing | – |
| 05 Aug 2026 | Second quarter 2026 financial results and corporate updateSource: SEC filing | – |
| 23 Jun 2026 | Clinical collaboration with Zumutor Biologics to evaluate ZM008 with LOQTORZISource: investbamboo.com | – |
Management commentary
“The totality of these interim data provides clinical proof of concept for tagmokitug, strengthens our confidence in the selected go-forward dose, and integrated development strategy.”
“This encouraging clinical evidence supports our strategy of targeting CCR8-positive regulatory T cells to overcome immune resistance in cancer, and underscores Coherus Oncology’s scientific leadership in the emerging field of CCR8 Treg depletion.”
| Share price | $1.16 |
|---|---|
| Market cap | $179M |
| Revenue (annual) | $42M |
| 1-month price change | +1.75% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Coherus Oncology, Inc. announcing interim clinical data from the TREGCHECK development program.
Track Coherus Oncology, Inc. live
Get the next Coherus Oncology, Inc. SEC filing seconds after it lands.